Open Government Portal

The purpose of this Notice is to notify stakeholders that Health Canada has made changes to the opioid patient information handout entitled “Opioid Medicines – Information for Patients and Families”. Canada's Food and Drug Regulations were recently amended to require that a warning sticker and patient information handout be provided to patients, at the time of sale, with all prescription opioids that appear in Part A of the “List of Opioids”.

The Canada Energy Regulator (CER) is committed to engaging with Stakeholders and Indigenous Peoples to establish meaningful relationships through its ongoing activities. Engagement involves dialogue, sharing information and building relationships with Canadians about the CER’s regulatory processes and services. Through engagement we gather valuable input, share information and foster understanding of issues important to Canadians, to better inform our decisions and our work.

Health Canada publishes a table of all correspondence and meetings with stakeholders on the Meetings and Correspondence on Marketing and Advertising of Opioids page in which views, opinions and information are relayed with the intent to inform the development of policies, guidance or regulations related to the restriction of marketing and advertising of opioids.

[ARCHIVED] The Province of Nova Scotia recognizes the importance of foreign engagement and regularly engages in government to government and government to business relations globally. In order to ensure that effective and positive international government relations are developed and maintained, the Nova Scotia Department of Intergovernmental Affairs has been mandated to foster and promote intergovernmental /international relations globally. Developing and enhancing meaningful intergovernmental/international relationships is an incremental process. Intergovernmental/international relations can be achieved through a number of primary activities: out-bound trade and business missions; incoming trade and business missions; and Nova Scotia government to foreign government/foreign business promotion.

Health Canada is pleased to announce the release of five associated revised draft guidance documents on Post-Notice of Compliance (NOC) Quality Changes for pharmaceutical, biologic and radiopharmaceutical drugs for human use, for stakeholder consultation.

The Multi-stakeholder Forum (MSF) on Open Government supports ongoing dialogue between government and Canadian civil society on open government. Its mandate is to provide input and advice on the Government of Canada’s commitments on open government, identify new areas of focus, and build the open government community across Canada. The Multi-Stakeholder Forum is composed of twelve members, eight from civil society and four from the Government of Canada. The Open Government Partnership (OGP) considers having a Forum to be a best practice, creating a permanent mechanism for civil society guidance and oversight.

The National Energy Board (NEB) strives for meaningful engagement with the public and Indigenous groups, to provide fair opportunity to access information on our processes and how to participate effectively in them. As such, NEB staff make themselves available to the public and Indigenous groups in a variety of ways to provide information as well as to respond to questions. Engagement activities are conducted using a variety of methods:
Information Session,
Meeting,
Telephone or Video Conference Meetings,
Online WebEx (various locations),
Open House,
Presentation,
Workshop,
Town Hall. NEB Damage Prevention staff conduct Damage prevention-related compliance verification activities.

This report summarizes the input received from partners who participated in the Department of Justice Canada’s initial engagement inviting First Nations, Inuit and Métis partners to discuss the modernization of the Privacy Act. These initial discussions took place from spring 2020 to spring 2021. This report also outlines next steps for further engagement with First Nations, Inuit and Métis partners on Privacy Act modernization. The purpose of sharing this report at this time is to let partners know what we have learned so far through this engagement process, to provide a common basis for continuing the conversation.

Summary of feedback received from the consultation on the Draft Guidance on Personal Production of Cannabis for Medical Purposes.

Health Canada is issuing this notice to clinical trial sponsors to clarify key obligations under the Food and Drug Regulations (FDR) for various types of cannabis-based clinical research.